维普期刊资源整合服务平台（V6.5）

86篇 您的检索式：作者名="Kaluski"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up显示文摘	Shira Zelber-Sagi Roni Lotan Amir Shlomai Muriel Webb Gil Harrari Assaf Buch Dorit Nitzan Kaluski Zamir Halpern Ran Oren	2012	Journal of Hepatology2012，，5：	4
2	Non‐alcoholic fatty liver disease independently predicts prediabetes during a 7‐year prospective follow‐up显示文摘	Shira Zelber‐Sagi Roni Lotan Oren Shibolet Muriel Webb Assaf Buch Dorit Nitzan‐Kaluski Zamir Halpern Erwin Santo Ran Oren	2013	Liver Int2013，，9：	3
3	Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures显示文摘	ShiraZelber‐Sagi DoritNitzan‐Kaluski ZamirHalpern RanOren	2006	Liver International2006，，7：	2
4	Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure显示文摘	Cotter G Kiowski W Kaluski E	2001	Eur J Heart Fail2001，3，4：	1
5	L-NMMA (a nitric oxide synthase inhibitor)is effective in the treatment of cardiogenic shock显示文摘	Cotter G Kaluski E Blatt A	2000	Circulation2000，101，：	1
6	A large food-borne outbreak of group A streptococcal pharyngitis in an industrial plant: potential for deliberate contamination 显示文摘	Kaluski DN Barak E Kaufman Z	2006	IMAJ2006，8，：	1
7	Tezosentan(an intravenous endothelin receptor A/B antagonist)reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure显示文摘	Cotter G Kicwski W Kaluski E	2001	Eur J Heart Fail2001，3，4：	1
8	RITZ-5:randomized intravenous tezosentan(an endothelin-A/B antagonist)for the treatment of pulmonary edema:a prospective,multicenter,doubleblind,placebo-controlled study显示文摘	Kaluski E Kobrin I Zimlichman R	2003	J Am Coll Cardiol2003，41，2：	1
9	Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrese in blood pressure in patients with congestive heart failure显示文摘	Cotter G Kiowski W Kaluski E	2001	Eur J Heart Fail2001，3，4：	1
10	Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study 显示文摘	Kaluski E Cotter G Leitman M	2007	109 (4): 273--2802007，109，4：	1
11	Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema显示文摘	Cotter G Metzkor E Kaluski E	1998	Lancet1998，351，9100：	1
12	Fractional flow re-serve (FFR) : changing the practice of interventional cardiology显示文摘	Kaluski E Waller AH Rudzinski W	2012	Minerva Cardioangiol2012，60，5：	1
13	Influence of conduction distur- bances on clinical outcome in patients with acute myocardial infarc- tion receiving thrombolysis (results from the ARGAMI- 2study)显示文摘	Abidov A Kaluski E Hod H	2004	Am J Cardiol2004，93，：	1
14	Predictors of postprandial triacylglycerol response in children: The Columbia University Biomarkers Study显示文摘	Couch SC Lsasi CR Karmally W Blaner WS Starc TJ Kaluski D	2000	Am J Clin Nutr2000，72，5：	1
15	Inflammatory and neurohor monal activation in cardiogenic pulmonary edema: implications on the pathogenesis and outcome of acute ischemic versus non ischemic acute heart failure显示文摘	Mio O Cotter G Kaluski E	2003	Am J Cardiol2003，92，：	1
16	LINCS: L-NMMA in cardiogenic shock: preliminary results from a prospective randomized study显示文摘	Cotter G Kaluski E Milovanov O	2002	Journal of the American College of Cardiology2002，39，5：	1
17	High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema显示文摘	Sharon A Shpirer I Kaluski E	2000	J Am Coll cardiol2000，36，3：	1
18	RITZ-5:randomized intravenousTeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary e-dema:a prospective,multicenter,double-blind,placebo-controlled study显示文摘	Kaluski E Kobrin I Zimlichman R	2003	JAm Coll Cardiol2003，41，2：	1
19	Clinical and hemodynamic effects of bosentan dose optimization in symp- tomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - a multi- center randomized study 显示文摘	KALUSKI E COTrER G LEITMAN M	2008	Cardiology2008，109，：	1
20	Osteopontin in cardiovas-cular disease:a potential therapeutic target显示文摘	Waller AH Sanchez-Ross M Kaluski E	2010	Cardiol Rev2010，18，3：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示